CD19 and diffuse large B-cell lymphoma: CD19 antigen represents another target and tafasitamab, a humanized anti-CD19, demonstrated clinical activity as a monotherapy in relapsed or refractory B cell NHL and in combination with lenalidomide in patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) [62, 63].